VIRAX BIOLABS GR.DL-,001

Virax Biolabs has agreed an exclusive supply contract with Fosun Diagnostics for the ImmuneSelect research portfolio in Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia for an initial term of five years. Virax shares rose sharply pre-market, driven by the company's small market capitalization and a recent 1:25 share consolidation. The contract covers research products only and does not include the ViraxImmune diagnostic platform currently in development. The economic impact will depend on whether the framework agreement leads to regular purchase orders in the coming quarters. » More on finanzen.net

The wholly owned subsidiary Virax Biolabs (UK) Limited has received ISO 13485:2016 and ISO 9001:2015 certifications; the certificates were issued on 18 February and are valid until 17 February 2029. The standards cover the design, development and manufacture of components and kits for immunological assays as well as product-specific quality management processes and are intended to support the development of diagnostic technologies for post-acute infectious syndromes, including Long-COVID. Virax is also evaluating laboratory services in the US and is advancing clinical validation work with the ADJUST Center at Emory University, while the stock, despite heavy price losses, shows a high liquidity ratio according to InvestingPro. » More on de.investing.com